SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV

PMPA 在 HIV 中的安全性、耐受性、药代动力学和抗病毒活性

• 批准号: 6115494
• 负责人: STEVEN Grant DEEKS
• 金额: $ 3.1万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115494
• 关键词: AIDS therapy; HIV infections; adenine analog; antiAIDS agent; clinical research; clinical trial phase I; drug screening /evaluation; helper T lymphocyte; human subject; human therapy evaluation; pharmacokinetics; phosphonate; prodrugs

The purpose of this study is to evaluate the safety and pharmacokinetics of single and multiple doses of PMPA pro-drug administered orally to HIV- infected patients and to evaluate the anti-HIV activity of PMPA pro-drug, as demonstrated by increases in CD4 cell counts and decreases in HIV RNA, when administered orally as a single dose and daily for four weeks to HIV- infected patients with CD4 cell counts >200 cells/mm3.

本研究的目的是评价其安全性和药代动力学。 单剂量和多剂量PMPA前体药物口服给HIV- 并评价PMPA前体药物的抗HIV活性， 正如CD4细胞计数增加和HIV RNA减少所表明的那样， 当单剂量口服并连续四周每日服用艾滋病毒时- 感染患者的CD4细胞计数为200个/mm~3。